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Abstract: A model describing the response of the growth of single human cells in the 
absence and presence of the anti-cancer agent topotecan (TPT) is presented. The model 
includes a novel coupling of both the kinetics of TPT and cell cycle responses to the 
agent. By linking the models in this way, rather than using separate (disjoint) approaches, 
it is possible to illustrate how the drug perturbs the cell cycle. The model is compared to 
experimental in vitro cell cycle response data (comprising single cell descriptors for 
molecular and behavioural events) – showing good qualitative agreement for a range of 
TPT dose levels. 
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1. INTRODUCTION 
 
In this paper, an approach is described in which a coupled mathematical model has been 
developed that is capable of describing the in vitro drug kinetics of the anti-cancer agent 
topotecan (TPT) for single human osteosarcoma cells linked to primary biological (cell 
cycle) responses. The model offers the possibility of demonstrating both the dynamic and 
temporal interactions of active drug delivered to its DNA-associated molecular target and 
the downstream impact on cell growth and death. Live-cell data generated from new 
experimental procedures have been used and these procedures were developed to meet 
the demands of model comparison/validation [1]. In order to do this a series of robust 
quantitative laboratory assays have been designed to track and measure time-integrated 
events at the single cell level. Acquired data are used for parameter estimation and model 
simulation to further investigate the interactions of the drug with its target and possible 
routes for cellular evasion of drug action (i.e. drug resistance). The aim of this study was 
to assess the possibility of linking an existing drug kinetic model (for TPT) with a basic 
model for cell cycle dynamics [2]. Ultimately, a robust and validated version of such a 
generic model could be used to design and predict the consequences and potential failure 
of drug treatment regimens. 
In Section 2 an outline of coupled drug kinetic – cell cycle response modelling and the 
underlying biochemistry for TPT is provided. The mathematical model developed is 
described in Section 3 and the methods for data collection and database generation are 
given in Section 4. The parameter estimation approach is presented in Section 5. Results 
from the parameter estimation using the experimental data are provided in Section 6. 
 
2 BACKGROUND 
 
2.1 Coupled Drug Kinetics/Cell Cycle Response Modelling 
In general the relationships between drug kinetics and the drug’s effect on the cell cycle 
are extremely complicated, especially when the perturbed biological system being 
modelled expresses discrete events within a heterogeneous cellular population. The 
linking of drug kinetics and cell cycle models to describe the kinetics for heterogeneous 
cell populations is relatively new. A recent model, developed independently by Alarcón 
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et al. [3] considers an approach that uses the cell cycle as a descriptor of the biological 
response.  A current drawback is the difficulty in obtaining model validation or 
comparison with experimental data.  
Critical to the modelling of the cell cycle responses to the action of topotecan is the 
ability to undertake high temporal resolution monitoring of cell cycle progression 
enabling the tracking of a single cell in a non-invasive manner even within heterogeneous 
populations. The green fluorescent protein (GFP)-based probe has expression, location 
and destruction characteristics that shadow cyclin B1 dynamics in living cells [4]. The 
non-perturbing stealth reporter performance has been validated on high content to high 
throughput detection platforms comprising multi-well high-throughput screen (HTS) 
imaging, single cell kinetic-tracking and multi-parameter flow cytometry [4, 5]. Cyclin 
B1-GFP tracking provides sub-phase information on cell cycle progression in parallel 
with morphological landmarks and DNA content analysis (Figure 1a). The continuous 
progression of cell cycle traverse and encoded molecular readouts in cell lineages (Figure 
1b) has been tracked, enabling the extraction of data with subsequent linking to the 
phenotypic cellular behaviour in response to topotecan treatment. These experimental 
data provide the fundamental information upon which the coupled drugs - cell cycle 
model is both developed and confirmed. 
 
(Figure 1 in here) 
 
 
2.2 Introduction to TPT: Action of the drug 
The anti-cancer agent considered here is TPT. It was selected on the basis of the 
experimental and clinical evidence for its primary cytotoxic activity against lung, breast 
and ovarian cancers [6]. TPT is a water-soluble derivative of camptothecin (CPT), an 
alkaloid isolated from the tree camptotheca acuminata, and acts as a DNA topoisomerase 
I, (topo I), inhibitor [7]. Topo I is a nuclear enzyme involved in DNA replication and 
repair. The enzyme unwinds supercoiled double stranded DNA (dsDNA) by temporarily 
binding to and cleaving one of the strands, forming a ‘cleavable complex’. DNA cleavage 
and ligation reactions catalysed by the enzyme are tightly controlled and are normally 
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barely detectable. The cleavage is coupled with religation to restore continuity to the 
DNA complex (Figure 2(a)). In the presence of TPT, the cleaved DNA-topo I complex is 
stabilised, effectively inhibiting religation and resulting in accrual of complexes each 
sequestering a strand-break (Figure 2(b)). The drug-induced single-strand breaks are 
reversible upon drug removal since the drug is non-covalently associated with DNA in 
forming the cleavable complex. Such lesions are considered non-toxic as they can be 
easily repaired/reversed. However, as replication proceeds double-strand breaks can be 
generated by the collision of a replication fork with the trapped complex – these lesions 
being responsible for the primary cytotoxic effects of TPT. 
 
(Figure 2 in here) 
 
TPT is of particular interest since the agent has intrinsic specificity for the DNA 
replication period in terms of the origin of drug responses and in terms of the growth and 
division cycle for outcomes (Figures 3 and 4). The mammalian somatic cell cycle 
comprises four distinct phases. In G1, the chromosomes are unreplicated and the cell is 
uncommitted to division. During transition from this phase to S phase the cell commits to 
replication if DNA integrity is not compromised. DNA is then replicated and paired 
chromatids form. This is followed by the G2 phase where chromosomal material is 
prepared by the surveillance of its integrity (e.g. persistence of double-strand breaks 
sensed at a checkpoint) prior to commitment to mitosis. In M phase the nuclear 
membrane is lost, chromatin condenses and sister chromatids are separated with each 
daughter cell receiving a copy of each.  Subsequently, the diploid 2n complement of 
chromosomes decondense in each daughter cell and the nuclear membrane is re-formed 
as cytokinesis is completed.  The processes involved are distinct and tightly regulated 
both temporally and spatially [8]. For modelling purposes the cell cycle may be thought 
of as comprising two alternative states: G1 and S-G2-M separated by irreversible Start 
and Finish transitions, as defined by Tyson and Novak [2]. Start is defined as where the 
cell begins replication and Finish where the DNA replication is complete. Finish cannot 
occur if there have been any problems with DNA replication or chromosome alignment 
(Figure 4). Since TPT is believed to be S-phase specific many cells may resist the agent’s 
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effects by failing to enter S phase (i.e. attempt to replicate DNA) during a finite exposure 
[9]. Blocking entry to S-phase halts the expansion of the cell population (i.e. cytostasis) 
and under some conditions can cause cell death (i.e. apoptosis). 
 
(Figure 3 in here) 
 
(Figure 4 in here) 
 
 
3. THE COUPLED DRUG KINETICS-CELL CYCLE MODEL 
 
Figure 5 provides a schematic for the coupled drug kinetics – cell cycle model. Separate 
models have been developed for the cell cycle and drug kinetics. These both contain the 
relevant basic physiology and biochemistry and are coupled together in such a manner 
that it is possible to illustrate how the drug perturbs the cell cycle. The TPT kinetics 
model describes the chemical reactions and partitions that occur when the drug moves 
from the medium, cytoplasm and then nuclear compartments. The active, closed-ring 
(lactone) form of TPT (TPT-L) undergoes reversible hydrolysis to an open-ring (hydroxy 
acid) form (TPT-H). This reaction is pH-dependent: the active and inactive forms 
predominate at low pH (<4) and high pH (>10) respectively [10].  
 
(Figure 5 in here) 
 
The same notation used by Evans et al. [11] is adopted, where concentrations of TPT-L 
and TPT-H are defined by L and H with subscripts, m, e, c and n defining the medium, 
extracellular, cellular and nucleic regions respectively. It is assumed that: (i) all the drug 
in the nucleus is bound and only TPT-L binds to DNA, and (ii) elsewhere reversible, pH-
dependent hydrolysis occurs. The latter is modelled using an elementary linear two-
compartment model, where rate constant omk  defines the ring opening for TPT-L and cmk  
the ring closing for TPT-H. In the cytoplasm the corresponding rate constants are ock  and 
cck  respectively. The mixing between the medium and extracellular regions is modelled 
 6 
by first-order flows. The parameter 
mik  refers to the flow into the extracellular region 
from the medium and 
mok , the flow out of the extracellular region into the medium. The 
flow between the extracellular and cytoplasm is also modelled as first-order. Note that 
only TPT-L crosses the plasma membrane (as observed experimentally). The rate at 
which TPT-L binds to DNA is assumed proportional (with rate constant, 
bk ), to the 
product of the concentration of TPT-L in the cytoplasm, )(tLc  and free binding sites 
)(tBF . The parameter TB  denotes the total concentration of available DNA binding sites, 
and, by mass conservation, the concentration of free sites is given by )()( tLBtB nTF , 
where )(tLn  is the instantaneous concentration of bound drug. Dissociation of bound 
drug is assumed to be linear with rate constants 
dlk  or dhk  for TPT-L and TPT-H 
respectively. The set of ODEs describing the system is given by: 
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1 , 
n
c
V
V
2 , and cem VVV ,,  and nV  denote the volumes of 
the extracellular location (Ve) to drug medium (Vm), extracellular location to cytoplasm 
(Vc) and nucleus (Vn) to cytoplasm.  The cellular volumes correspond to the total volume 
for each cell type, where it is assumed, for simplicity, that these volumes are the same 
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across cell types.  The total volume, VT, of the medium is equal to the sum of the volumes 
of the medium and extracellular location, 
 i.e., 
e 0e
T m e e
0 0
1V vV
V V V V
v v
.  
The drug is administered as a bolus injection of active form only into the medium at time 
t = 0 (to give a concentration of D μM with respect to the total volume, VT) and so the 
initial conditions for the model are given by: 
DLm )1()0( 0  
and 
 
0)0()0()0()0()0()0( ncceem LHLHLH .  (2) 
 
The pH level at which the experiments were undertaken was 7.2. Estimated values for the 
drug kinetics model parameters are provided in [11].  
After one hour the medium is exchanged for drug-free medium (washout) and the cell 
tracking begins.  To model washout at t = 1 h the variables relating to drug in the medium 
are instantaneously set to 0, that is: 
 (1) (1) (1) (1) 0.m m e eL H L H      (2A) 
All other variables within the drug kinetic model are unaffected by this event. 
The drug kinetics model is coupled to the cell cycle model as shown in Figure 4. The 
coupling between Cyclin B1 and bound TPT in the nucleus is constrained to only have an 
effect in the S-G2-M state of the cell cycle process.  Following the approach of Tyson 
and Novak [2] (for the synthesis of Cdc20) this constraint is achieved via the 
incorporation of a suitable Hill function in the relevant governing equation.  The coupling 
involves a signal transduction cascade by which phosphorylation changes in the 
chromatin environment indicate the magnitude and persistence of lesions. Damage 
induces genomic stress response pathways, with negative feedback controls, that engage 
inhibitory pathways for halting cell cycle progression though master cell cycle regulators. 
Here the drug kinetics model has been linked to the master cell cycle regulators via a 
theoretical damage variable ([Dam]), which is itself driven by the kinetic model within 
the cell cycle state constraint.  Later generations of the integrated model will focus on the 
exact nature of the stress-signalling linkage. The basic cell cycle model used is one that is 
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regulated by the interaction of cyclin dependent kinases (Cdks) and cyclin B1 with the 
Anaphase Promoting Complex (APC) group of proteins. Accordingly, APC negates Cdk 
activity by degrading the major mitotic cyclin (cyclin B1) while Cdk/Cyclin B1 inhibits 
APC activity. With regard to the cell cycle, at G1, Cdk activity is low and cyclin B1 is 
rapidly degraded. At Start, cyclin B1 levels are promoted. Cdk levels rapidly rise and are 
maintained through S, G2 and M (see Figure 6). At Finish, APC proteins are activated 
and specific proteins degraded.  
 
(Figure 6 in here) 
 
APC consists of polypeptides and auxiliary proteins: Cdc20 and Cdh1 which are key to 
targeting and marking those proteins that are to be degraded at the end of M to allow the 
system to return to G1. Cdc20 and Cdh1 are controlled differently by cyclin B which 
activates other features in the model. The model equations are based upon those of Tyson 
and Novak [2] describing mechanisms occurring in yeast cells. The system of equations 
employed in our model is a modified version of these based upon the action of TPT and 
using appropriate parameter values derived from live osteosarcoma cell data obtained 
from our experiments (see Section 4).  
 
At the core of the cell cycle model are the equations governing the behaviour of Cyclin B 
with Cdh1. The core equations governing interaction of Cyclin B with Cdh1, in the 
presence of TPT, are given by: 
 
 1 2 2 2
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d
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t
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where the components in the square brackets refer to concentrations, m represents the 
mass of the cell, m  is the maximum size to which a cell can grow, μ is the specific 
growth rate, ki s are rate constants and Ji s are relevant Michaelis-Menten constants. In 
addition, when [CycB] falls below a certain threshold (taken to be 0.1 [2]) cell division 
occurs so that m → m/2.  It is assumed that the reaction between TPT and topo I is 
instantaneous, (as observed experimentally), and the level of the latter is constant. Values 
for the parameters are defined in Table 1. These are characterised by those given in 
Tyson and Novak [2] and have been appropriately scaled with respect to time according 
to the live-cell data provided from our experiments. 
 
 
4. EXPERIMENTAL DATA COLLECTION AND DATABASE GENERATION 
 
Generation of single-cell experimental data for cyclin B1 dynamics and incorporation 
into a database has provided the necessary resources for model validation/parameter 
estimation. High-resolution fluorescence cell tracking was performed with cells seeded 
into a multi-well coverslip-bottomed plate. Each well represents a different treatment 
regimen (a dose range for TPT 1-10 µM bolus for 1 h).  The cultured dishes were placed 
onto a time-lapse instrument designed to capture transmission phase and cyclin B1-GFP 
fluorescence images. Sequences were captured every 20 min for 48 h, in triplicate per 
treatment regime.  
At the end of the experiment the images were stacked and saved in *.stk or *.AVI format. 
FluroTRAK [12], an in-house software package written in Perl and developed by the 
Cardiff co-authors, was used to link and interact with commercial image analysis 
software, Metamorph (Molecular Devices Ltd, UK), to encode and transform the images 
into a parameterised database (see Figure 7a). The implementation of the lineage 
databases can be found at http://biodiversity.cs.cf.ac.uk/cymart/.  CyMART provides the 
home for a number of databases where the core concept is to develop a bioinformatics 
environment where analysis tools efficiently encode microscopy images into numbers 
and deposit the encoded data in relational databases.  
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A typical time-lapse microscopy image sequence shows cells traversing the cell cycle and 
fluorescence changes as the cell progresses to mitosis from G1, individual cells ramp up 
cyclin B1-GFP expression (become brighter), and a translocation event (cytoplasm to 
nucleus) occurs just before mitosis. A typical cell lineage over 48 h illustrates a simple 
progression of a progenitor cell (B) dividing into two daughter cells and cellular 
information at two levels (i) phenotypic behaviour (division represented by M) and (ii) 
fluorescence reporter readout (cyclin B1-GFP, hence cell cycle position) at the single cell 
level. The lineage shown in Figure 7a consists of three overlapping and inter-related 
tracks. The continuous cell cycle progression between the two landmarks, represented by 
mitotic events (M1 to M2) at either end, was demonstrated for a typical cell originally in 
G2. The continuous cyclin B1 GFP-track was similarly extracted for single cells in G2 
treated with 0, 0.1, 1.0 and 10 µM topotecan concentrations (Figure 7b). The principal 
effect was an extension between the two mitotic landmarks, and an increase in 
intermitotic time, including an extended delay in G2 for the cell treated with 10 M TPT.  
 
(Figure 7 in here) 
 
5. MODEL PARAMETER ESTIMATION 
 
Using estimated drug kinetics model parameters [11] the FACSIMILE software package 
(MCPA Software, UK) was used to fit the coupled drug kinetics-cell cycle model to the 
GFP fluorescence data. This computer-modelling tool is designed to numerically solve 
differential equations, with a particular focus on modelling the kinetics of physical and 
chemical systems. A particular advantage of this package is the robust numerical 
integrator that is able to handle stiff systems, that is, systems with widely varying rate 
constants (a property of the coupled model). The numerical integrator can solve all the 
ordinary differential equations of the model simultaneously and uses the parameter-fitting 
option available to fit the simulated output of the model to the experimental data. The 
result of this optimisation process is the estimation of the model parameters. 
Parameter estimation is treated as an optimisation problem in which a given performance 
index, measuring overall closeness of fit, is minimised. This closeness of fit is measured 
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by the residual sum of squares (RSS), that is, the sum of the squared errors (between the 
model and the experimental data) at each time point making the optimisation a least 
squares problem.  In FACSIMILE the RSS is given by: 
 
2
obs sim
1
( ) ( )n j
j
y j y t
RSS  (4) 
where sim ( )jy t  is the model output at the j
th
 sampling time (tj) and obs ( )y j  is the 
corresponding experimental data point. An estimate for the standard error for the output 
is provided by e R , in which e = 0.1 is the estimated overall accuracy of the data (an 
assumed overall error of 10%) and R is the range for sim ( )jy t  [13].  This approach is also 
referred to as a weighted least squares method as the random error at each sampling time 
tj is multiplied by a constant weight, 
21 , resulting in normalisation of the residuals if  
can be chosen to be the standard deviation for the random errors. 
For this study the model output, ysim(t), is taken to be a linear function of cyclin B 
concentration, [CycB], that is 
 
sim( ) [CycB]y t  (5) 
and the observation parameters  and β are estimated from the experimental data.  Since 
the live cells are being tracked in time these parameters are permitted to change (if 
appropriate) at cell division, but remain constant during an individual cell cycle.  The 
only other parameters estimated from the live-cell data are those relating to the kinetic-
cell cycle linking, namely, 
2k  and 11k , which are permitted to change with dose but are 
otherwise constant. 
Confidence levels provide a statistical measure of how well the parameters are defined by 
the model and the data.  FACSIMILE works in terms of internal parameters that are the 
natural logarithms of the given model parameters.  Information is also returned on the 
estimated correlation between the estimated parameters and the standard deviation of the 
natural logarithm (SDLN) of each of the well-determined parameters, p
0
, which is 
estimated from the variance-covariance matrix of p-p
0
 [13]. 
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6. RESULTS 
The parameter values and estimated parameter values, with estimates for their 
confidences are provided in Table 1. The plots shown in Figure 8 show three typical 
traces for the growth of a cell in the absence and presence of 1 and 10µM TPT. The live-
cell data are denoted by the grey circles and the simulated data by the solid black curve.  
 
(Table 1 in here) 
(Figure 8 in here) 
 
The model predicts when cell division occurs since this corresponds to the transformation 
in the cell mass variable m m/2 (when [CycB] drops below a given threshold, in this 
paper 0.1) that is preceded by the spikes in the data. As the cell divides the growth of 
either one of its daughter cells can be monitored. The corresponding simulation shows a 
good qualitative representation of the experimental data, even for the cases where TPT 
has been administered (Figures 8 (b) and (c)). A key feature of the estimation is that the 
main cell cycle parameters are fixed across doses at scaled (with respect to time) values 
of those used by Tyson and Novak [2]. In virtually all cases the estimated parameters 
have low SDLNs corresponding to high confidence in their values. The one exception 
corresponds to the G2 phase of the second-generation daughter cell in Figure 8(c) and is 
due to the low signal-to-noise ratio in the experimental data. 
From Figure 8 it can be seen that the drug extends the overall time between mitoses. The 
main outcome from the model is obtaining the correct time-event characteristics 
successfully. It is noted that the model under predicts the spikes in the experimental data. 
However, these spikes correspond to morphological changes in the cell during mitosis. 
As the cell grows, its shape changes and just before division the cell ‘rounds up’ 
becoming spherical in shape. The light reflected back, a measure of the fluorescence, is at 
its most intense at this stage resulting in a false peak in the data. The parameter 
estimation attempts to allow for this by capping the data at some chosen fixed level. 
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7. CONCLUDING REMARKS 
A coupled, drug kinetics – cell cycle model with the relevant cell biochemistry has been 
developed to describe cell regulation with time. The model provides novel linking 
between existing drug kinetic and a cell cycle models and is able to describe the effect 
that varying doses of TPT have on cell growth. Model simulations have been compared 
with live-cell experimental data and found to give good qualitative agreement. In 
addition, in virtually all cases the unknown model parameters were estimated to a high 
level of confidence. The close qualitative agreement between model and experimental 
data was obtained by estimating only those parameters that are associated with the 
coupling or observation of the system. 
The next step is to extend the model across different cell lineages and different treatment 
scenarios to provide greater robustness and validation. Such a robust and well-validated 
model could ultimately be used to test scenarios applicable for drug treatment and design, 
for example, introducing delayed response characteristics. In addition, this will extend the 
field of application for the generic model developed. 
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Table Legend 
 
Table 1. 
Table of parameter values.  Where parameters are estimated from the live-cell data SDLN 
values are provided (in brackets).  For the observation parameters  and β different 
estimates (where appropriate) are obtained before (top) and after (bottom) the second 
peak. 
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Table 1 
 
Parameter Value 
1k  1.5975 10
-1
 
2k  1.5975 10
-1
 
2k  3.9937 10
0
 
3k  3.9937 10
0
 
3k  3.9937 10
+1
 
4k  1.3978 10
+2
 
3J  0.04 
4J  0.04 
5J  0.3 
 3.9937 10
-2
 
*m  10 
 Control 1 μM TPT 10 μM TPT 
 68.31 (0.15) 
95.88 (0.27) 
87.49 (0.38) 
110.53 (0.28) 
34.17 (1.18) 
β 
65.79 (0.07) 
53.54 (0.07) 
40.54 (0.17) 
46.06 (0.16) 
59.08 (0.12) 
36.67 (0.23) 
2k  0 0.580 (0.01) 0.414 (0.001) 
11k  0 0.666 (0.02) 0.441 (0.02) 
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Figure Legends 
 
Figure 1:   
(a) Human osteosarcoma cells (U-2 OS cells) expressing a cyclin B1-GFP stealth reporter 
(left panel) and a corresponding transmission image (right panel) to identify all the cells 
in the field of view. The cells are expressing different levels of cyclin B1-GFP and are 
hence at all different stages of the cell cycle.  (b) Capturing an image every 20 minutes 
enables single cell tracking, providing a means of continuous cell cycle monitoring for 
every cell.  This provides the experimental data for building and validating the cell cycle 
model.  
 
Figure 2:  
Diagram of the action of topoisomerase I during the cell cycle in (a) the absence and (b) 
the presence of TPT (after Bailly [2]). 
 
Figure 3: 
Schematic of the cell cycle showing the main phases and the Start and Finish transitions. 
 
Figure 4: 
Schematic of the cell cycle showing the Start and Finish transitions.  In addition, the key 
components of the basic cell cycle model are indicated: cell cycle regulation is controlled 
by the interaction of cyclin dependent kinases (Cdks) and cyclin B1 with the Anaphase 
Promoting Complex (APC) group of proteins. APC negates Cdk activity by degrading the 
cyclin B1 while Cdk/Cyclin B1 inhibits APC activity. 
 
Figure 5: 
Schematic of the drug kinetics-cell cycle model.  The circular compartments represent 
variables within the drug kinetics model, which affects the cell cycle model via an 
indirect inhibition of cyclin B.  The coupling involves a signal transduction cascade by 
which phosphorylation changes in the chromatin environment indicate the magnitude and 
persistence of lesions. 
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Figure 6: 
The relationship between Cdk-Cyclin B and APC during the cell cycle.  At G1, Cdk 
activity is low and cyclin B1 is rapidly degraded and then at Start, cyclin B1 levels are 
promoted. Cdk levels rapidly rise and are maintained through S, G2 and M while at 
Finish, APC proteins are activated and specific proteins degraded. 
 
Figure7:  
Encoded cell lineage with corresponding molecular readout. (a) An exemplar lineage 
encoded from a real cell using FluroTRAK.  Progenitor cell (B) divides into two daughter 
cells 5 hours after the start of the experiment.  The north daughter (BN) again divides at 
27.66 hours into two daughter cells BNN and BNS while the south daughter BS failed to 
divide within the duration of the experiment. Three living cells (BNN, BNS and BS) at 
the end of the experiment yielded three tracks labelled as track 1 2 and 3 respectively. 
Continuous cyclin B1-GFP intensity from cytoplasm of track 1 is plotted from the 
encoded data as an example. (b) Similarly extracted continuous cyclin B1-GFP intensity 
tracks extracted from typical G2 cells responding to a dose range of topotecan (TPT).  
 
Figure 8: 
Model fits showing model predictions (solid lines) and Cyclin B data (dashed lines) 
against time (t), (a) in the absence of TPT, and presence of (b) 1μM and (c) 10μM TPT.  
An artefact of morphological changes during the final stages of mitosis is the over 
expression of cyclin B fluorescence giving to false peaks in the experimental data.  In an 
attempt to minimise the impact of this effect the data were capped. 
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 Figure 8(a) 
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Figure 8(c) 
 
 
 
